937014-94-3

Upstream product

• 683-57-8 bromo-acetic acid amide 
• 207801-52-3 N-[5-bromo-1H-pyridin-(2Z)-ylidene]-4-methyl-benzenesulfonamide 
• 1072-97-5 5-bromo-2-pyridylamine 
• 98-59-9 p-toluenesulfonyl chloride 
• 144-48-9 iodacetamide 
• 207801-52-3 N-(5-bromopyridin-2-yl)-4-methylbenzenesulfonamide 
• 79-07-2 Chloroacetamide 

Downstream Products

• 947248-52-4 6-bromoimidazole[1,2-a]pyridine-2-amine 
• 1162680-84-3 N-(6-bromoimidazo[1,2-a]pyridin-2-yl)acetamide 
• 947249-08-3 N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridine-2-yl)acetamide 
• 504413-35-8 N-(6-bromoimidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide 

Relevant academic research and scientific papers

HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF

The present disclosure provides heteroaryl compounds of formulas (I), (Ia) and (Ib), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosi

FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE

The invention relates to compounds of formula (I) for the regulation of phosphoinositides 3-kinases activity and related diseases.

BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS

Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE

Phosphatidylinositol (PI) 3 kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceuticall